During a roughly five week period in 2020, the Walt Disney Co.’s stock value surged from the $120 range to a price upward of $170. The company’s shares were buoyed, in part, by Pfizer’s successful Phase-3 vaccination trial and Disney’s second Direct-to-Consumer investor day.
The one-year anniversary of these events is approaching and, MoffettNathanson Senior Analyst Michael Nathanson notes, “the stock is seemingly stuck in neutral.”
Has the market — or Disney — gotten it right?
